SR9009

SR9009,which is currently under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice.Treated mice become lean,develop larger muscles and can run much longer distances simply by taking SR9009,which mimics the effects of aerobic exercise.If similar effects can be obtained in people, the reversal of obesity,metabolic syndrome,and perhaps Type-II diabetes might be the very welcome result.

SR9009 Application:

SR9009 affects the primary biological clock, which coordinates the rhythm of the body's activity with the 24-hour phase of day and night.

SR9009 Basic Info.

Product Name: SR9009

Synonyms: SR9009

CAS: 1379686-30-2

Use:reduce obesity in populations of mice. It binds to and activates a protein called Rev-ErbAα, which influences fat and sugar burning in the liver, production of fat cells, and the body's inflammatory response.

SR9009 Application:

SR9009 affects the primary biological clock, which coordinates the rhythm of the body's activity with the 24-hour phase of day and night.

Recent research show that activation of Rev-erbα with SR9009 resulted to enhanced metabolic activity in skeletal muscle tissue in both culture and in mice. The authors of this new research propose that Rev-erbα affects muscle cells by stimulating both the formation of new mitochondria (more known as the "power plants" of the cell) and the authorization of those mitochondria that are flawed.

If the effects of SR9009 on mice can securely be duplicated for people, the new drug may provide new treatments for obesity and its companions, metabolic syndrome and diabetes. Another area in which SR9009 or a similar drug may present significant benefit is to balance the loss of overall muscle conditioning which transpires as a side effect of reduced activity due to sickness or old age.